AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04691076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is administered by target-controlled infusion
Study NCT04691076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine is intravenously administrated
Study NCT04691076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl is intravenously administrated
Study NCT01730482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] AT1001
Description: 150 mg of \[14C\] labelled AT1001 will be administered as a solution (prepared by weighing 150 mg of AT1001 powder and dissolving in 100 mL of water). The entire solution will be swallowed orally. After ingestion of study medication, the dosing bottle will be rinsed with 50 mL of water and this will be ingested by the subject. This rinse procedure should be performed twice. Following the second rinse ingestion, the subjects should be instructed to drink additional water to bring the total volume ingested to 240 mL.
Study NCT02181088 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 RH5 low dose
Description: ChAd63 RH5 at 5 x 10\^9 vp
Study NCT02181088 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 RH5 full dose
Description: ChAd63 RH5 at 5 x 10\^10 vp
Study NCT02181088 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA RH5 low dose
Description: MVA RH5 at 1 x 10\^8 pfu
Study NCT02181088 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA RH5 full dose
Description: MVA RH5 at 2 x 10\^8 pfu
Study NCT03270501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Axial spondyloarthritis patients who don't have a good treatment response on 2 NSAIDs, will be treated with golimumab. After remission, the therapy will be stopped.~All patients will undergo a ileocoloscopy at baseline and, if positive, at time of remission.
Study NCT03980704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMPACT
Description: Administration of oral immunostimulating oral supplement
Study NCT03980704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: resource protein
Description: Administration of oral high-protein oral supplement
Study NCT02610114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Z-Score and computer algorithm
Description: In addition to the routine Z-score for zygote selection, if needed, the photographs of the zygotes already taken for quality and safety reasons are analysed using the new computer algorithm. Within a few minutes it generates a score, determining the quality of the cells. The two best cells upon Z-score result and new computer algorithm result are selected for first transfer.
Study NCT02610114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Z-Score
Description: After fertilisation pronuclei and nucleoli can be seen inside the cells by microscope. Routinely, the alignment of nucleoli can be used generating a score, the Z-score 1-4, established by Scott. Two zygotes getting the best Z-score are selected for cell culture and the cells that develop to embryo stage are used for first transfer.
Study NCT04097574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NPO-13: l-menthol
Description: 20 mL/site
Study NCT04097574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPO-13: l-menthol
Description: 20 mL/site
Study NCT01223781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback-based motor learning for PD
Description: Prior to freezing episodes, auditory stimulation is triggered
Study NCT02407600 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: FOSAPREPITANT (Emend)
Description: Uee of fosprepitant in EITHER first OR 2nd cycle of carboplatin containing combination chemotherapy in patients with advanced NSCLC
Study NCT02407600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOSAPREPITANT (Emend)
Description: Uee of fosprepitant in EITHER first OR 2nd cycle of carboplatin containing combination chemotherapy in patients with advanced NSCLC
Study NCT02407600 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Study NCT02407600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02395159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena™ IMS
Description: Prevena™ IMS is intended for the management of the surgical incision environment and surrounding healthy skin in patients with a risk of postoperative complications such as infections. This entails the maintenance of a closed environment around the incision by applying a negative pressure wound therapy system.~The corresponding dressing is known under the name Prevena™ Dressing. The layer closest to the skin comprises silver foil, which reduces the microbial colonisation of cells.
Study NCT02395159 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sterile plaster dressings
Description: standard wound management method of sterile plaster dressings
Study NCT02360878 — intervention group
Intervention type: DEVICE
Intervention: EndoBarrier Gastrointestinal Liner
Description: Implantation with the EndoBarrier
Study NCT01786577 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Both groups will undergo two MRIs at baseline and within 48 hours after surgery/non-surgery.
Study NCT01786577 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive assessment testing
Description: Both groups will undergo in-person baseline assessment of cognitive functioning as well as assessments at three weeks, three months and one year.
Study NCT02295618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard tracheal tube
Description: Intubation using Macintosh laryngoscope and standard tracheal tube
Study NCT02295618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETView VivaSight SL
Description: Intubation using ETView VivaSight SL
Study NCT01149018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol
Description: Oral solution of THC in concentration of 5mg/0.2ml. Dose regimen: 5mg 2-4 times/day as tolerated.
Study NCT01149018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally administered olive oil. Dose: 0.2ml 2-4 times a day as tolerated
Study NCT04518358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Expert Guiding Technology (GAINS) to Improve Live and Vocational Skills for Individuals with Developmental Challenges
Description: During the GAINS sessions, the Direct Support Professional (DSP) will follow the pre-programmed teaching protocol in the expert guiding technology. The system will provide step-by-step verbal prompts to the DSP throughout sessions. This includes which prompt to use for each step of the target skill, when to provide reinforcers, and which target task to work on. The system will also monitor the participant's (adults with ASD/ID) progress and notify the DSP if the target skill is mastered.
Study NCT03131609 — intervention group
Intervention type: OTHER
Intervention: Container
Description: Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
Study NCT03131609 — intervention group
Intervention type: OTHER
Intervention: Silver Impregnated Wipe
Description: Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
Study NCT03131609 — intervention group
Intervention type: OTHER
Intervention: Funnel
Description: Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
Study NCT03131609 — intervention group
Intervention type: OTHER
Intervention: Castile-soap wipe
Description: Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
Study NCT01869764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Description: Given PO
Study NCT01869764 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT01869764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01869764 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02394587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction
Description: A non-pharmacological approach to pain management.
Study NCT02394587 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness-based Stress Reduction
Description: A non-pharmacological approach to pain management.
Study NCT00965861 — intervention group
Intervention type: OTHER
Intervention: Tissue Registry Study
Description: If a patient consents to allowing the use of their tumor tissue sample(s) for testing/analysis at a future date, their name and information will be stored electronically in a registry that will be managed by SCRI. SCRI may then use the information contained in this registry (such as disease indication, demographic information, etc.) at any time in the future to select tissue samples on which to perform testing/analyses.
Study NCT01614392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High velocity low force Power Training
Description: Lower Extremity high velocity power training performed at lower external resistance (40% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
Study NCT01614392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low velocity high force Power Training
Description: Lower extremity low velocity power training performed at high external resistance (70% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
Study NCT04151576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy massage
Description: aromatherapy massage
Study NCT01637441 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic sacropexy
Description: under laparoscopic vision, the vesico-vaginal space is dissected until the level of the bladder neck. a synthetic non absorbable mesh is placed between the bladder and the vagina. the mesh is sutured to the vagina and the apex (vaginal apex or uterus) and anchored to the prevertebral ligament in front of the promontorium.
Study NCT01637441 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vaginal mesh
Description: after anterior sagittal colpotomy, the bladder is dissected under the fascia layer, and the paravesical fossa are entered. a synthetic non absorbable mesh is placed with 4 arms suspension (trans obturator or not). treatment of the apex is mandatory.
Study NCT00702299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
Study NCT00702299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
Study NCT00702299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Escalate doses in groups of 3 patients to 60mg per m2, 120 mg per m2, 500 mg per m2, 750 mg per m2, 1000 mg per m2
Study NCT00702299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biologic sample preservation procedure
Description: Plasma samples will be collected on the 1st course at baseline, 30 minutes, 60 minutes, 2 hours, 4 hours, 6 hours (if possible) and 24 hours after the first IP Alimta® dose.
Study NCT02851472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: Nitric oxide gas will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems adapted specifically for this study.
Study NCT02851472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo gas (nitrogen) will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems specifically adapted for this study.
Study NCT01521403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 3x500 mg/day for 10 days
Study NCT01521403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3x1 tablet per day for 10 days
Study NCT03638037 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D measurement
Description: Maternal serum 25- hydroxyl vitamin D level
Study NCT04235621 — intervention group
Intervention type: OTHER
Intervention: FSGS/TR-MCD
Description: This is a non-interventional study
Study NCT04235621 — intervention group
Intervention type: OTHER
Intervention: Diabetic Nephropathy (DN)
Description: This is a non-interventional study
Study NCT00834093 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epstein-Barr Virus Specific Immunotherapy
Study NCT01579929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225, Etoposide and Cisplatin
Description: In a standard, 3 + 3 dose escalation phase, two successive cohorts of ES-SCLC patients will receive LDE225 with etoposide and cisplatin with a dose of 200 mg to be reserved for de-escalation until the MTD is determined. Cohorts of at least 3 evaluable patients will be treated at each dose level of LDE225 (400 mg daily and 800 mg daily). One additional dose (200 mg daily) will be reserved for de-escalation. A minimum of 6 evaluable patients must be treated at the dose declared to be the MTD. Each cohort will consist of newly enrolled patients. An estimated total of 6 to 12 patients may be necessary to establish the MTD. Actual accrual will depend on the dose levels tested and the DLT observed. Upon completion of a minimum of four and a maximum of six cycles of LDE225 with etoposide and cisplatin, patients in each cohort with at least stable disease will receive maintenance LDE225 until disease progression or unacceptable toxicity.
Study NCT00248768 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial magnetic Stimulator
Description: a device which produces intense magnetic fields in the brain and activates cerebral neurons
Study NCT04071288 — intervention group
Intervention type: PROCEDURE
Intervention: total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes
Description: total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes; Burch colposuspension and mid-urethral sling operations for stress urinary incontinence
Study NCT02964091 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sofosbuvir/ledipasvir
Study NCT03193593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo- Single injection of saline into Pectoralis Muscle
Study NCT03193593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-001
Description: Single injection of EB-001 into Pectoralis Muscle
Study NCT02864056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Ancient Chinese form of mind/body gentle exercise; this will be done while standing to improve postural balance.
Study NCT03586466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BupreCare
Description: Subjects will receive their medication in a MedicaSafe device. Medication will be dispensed in accordance with the programmed treatment plan for each subject. Subjects will complete a Check-In remotely each week with their device.
Study NCT03586466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: Subjects will be given buprenorphine/naloxone as a component of Medication Assisted Treatment (MAT).
Study NCT03586466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone
Description: Subjects will be given buprenorphine/naloxone as a component of Medication Assisted Treatment (MAT).
Study NCT03586466 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MEMS
Description: Subjects will receive their medication in a MEMS pill bottle.
Study NCT02231359 — intervention group
Intervention type: DRUG
Intervention: Berodual® Respimat® solution for inhalation
Study NCT00309348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly measurement of graft flow
Study NCT03370432 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected at enrolment using questionnaires and interviews
Study NCT00606593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-078573 oral capsules at 25 and 100 mg and matching placebo
Description: 5-period, 5-treatment crossover: sequences: ABECD, BCADE, CDBEA, DECAB, EADBC DCEBA, EDACB, AEBDC, BACED, CBDAE Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
Study NCT00606593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-078573 and matching placebo
Description: ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
Study NCT04976543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nadroparin calcium-warfarin sequential anticoagulation
Description: The NWS therapy group were given a subcutaneous injection of nadroparin calcium every 12 hours for 1 month and switched to warfarin for 5 months. Warfarin was initiated at least 5 days before nadroparin calcium was stopped. International normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
Study NCT03068585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neovasculgen (Cambiogeneplasmid)
Description: treatment
Study NCT03174730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth Mindset
Description: The intervention is aimed at creating more flexible thinking about addiction to tobacco. Participants will be sent tips by email to help foster the belief that people can overcome addiction to smoking.
Study NCT03174730 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SmartQuit
Description: This is an Acceptance and Commitment Therapy based intervention designed a smoking cessation smartphone application.
Study NCT03174730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SmartQuit
Description: This is an Acceptance and Commitment Therapy based intervention designed a smoking cessation smartphone application.
Study NCT00992797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol 200.000 IU pr ampoule, 400.000 IU given at randomization day, followed by additionally 200.000 IU at week 5 if serum 25(OH)D \< 100 nmol/L. If serum 25(OH)D > 100 placebo will be given. The cholecalciferol will be given in orange juice.
Study NCT00992797 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Orange juice
Description: Orange juice at randomization day and at week 5.
Study NCT03830619 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: collect samples
Description: collect serum samples and clinical features
Study NCT02189733 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Caplacizumab
Description: Comparison of reconstituted lyophilised formulation versus liquid formulation of caplacizumab
Study NCT03358264 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: Amino acid supplement
Study NCT01707199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate + Sulphadoxine-pyrimethamine
Description: AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.~One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date.
Study NCT02422459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMMENCE
Description: ChrOnic pain self-ManageMent support with pain science Education and exerCisE (COMMENCE) consists of two visits with a physiotherapist per week over six weeks. One of the two visits is in a group setting, where the emphasis is on pain neurophysiology education and provision of self-management strategies. The second visit each week is an individualized, one-to-one session in which the focus is on providing support for implementing self-management strategies and developing of an individualized, goal-oriented exercise program.
Study NCT04788706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low level Laser Therapy and Russian electrical stimulation
Description: LLLT over three weeks followed by an eight-week receiving Russian electrical stimulation
Study NCT04788706 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser and Russian electrical stimulation
Description: Placebo laser over three weeks followed by an eight-week receiving Russian electrical stimulation